Savage William Jacob 4
Research Summary
AI-generated summary
Disc Medicine (IRON) CMO William Savage Receives Awards
What Happened
- William Jacob Savage, Chief Medical Officer of Disc Medicine (IRON), received two equity awards reported on Feb 10, 2026: 17,000 restricted stock units (RSUs) and a derivative award covering 25,500 shares. Both awards were reported at $0.00 (no cash changed hands). These are grants, not open-market purchases or sales.
Key Details
- Transaction date and price: Feb 10, 2026; both items reported at $0.00 (Form 4 code A — award/grant).
- Award types and vesting:
- 17,000 RSUs (F1): vest in four annual 25% installments beginning Feb 15, 2027, subject to continued service.
- 25,500 derivative award (F2): described as an option whose underlying shares vest in 48 equal monthly installments beginning March 10, 2026, subject to continued service.
- Shares owned after transaction: Not disclosed in this filing.
- Filing timeliness: Report filed on Feb 11, 2026 for a Feb 10, 2026 transaction (filed promptly).
- No indication in the filing of sales, tax-withholding shares, or a 10b5-1 plan.
Context
- RSUs convert to common stock only as they vest; the RSU grant does not represent immediate free shares. The derivative award is subject to a monthly vesting schedule and is contingent on continued employment. Because these are company grants, they are routine compensation/retention actions and should not be interpreted as a direct buy or sell signal by the insider.